Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
A. baumannii is most commonly responsible for urinary tract infections, ventilator-associated pneumonia, central line-associated bloodstream infections, persistent wound infections and meningitis
Recce Pharmaceuticals Limited the Company developing a new class of synthetic anti-infectives, is pleased to report promising results from its latest study on the efficacy of RECCE® 327 (R327) against multidrug- resistant (MDR) World Health Organization (WHO) priority pathogen Acinetobacter baumannii (A. baumannii). The study was conducted at Recce’s Anti-Infective Research (AIR) unit within Murdoch Children’s Research Institute.
“These outstanding results highlight the potent efficacy of R327 in combating MDR bacteria, a significant global health challenge,” commented James Graham, CEO of Recce Pharmaceuticals. “The ability of R327 to achieve such substantial reductions in bacterial load and maintain its effectiveness over 24 hours is a testament to its potential as a leading anti-infective treatment. We are excited about these findings and their implications for the future of infection management.”
Dr. Sohinee Sarkar, a leading researcher at Murdoch Children’s Research Institute, added, “The significant bactericidal activity observed with R327, particularly its ability to reduce bacterial presence to below the limit of detection, marks a major advancement in our fight against resistant pathogens. The sustained efficacy of R327 compared to ciprofloxacin underscores its potential as a superior treatment option. These results are promising and pave the way for further development and application of R327 in clinical settings.”
The study demonstrated R327’s bactericidal activity when compared to placebo and ciprofloxacin in 1-hour post treatment and at 24-hours post treatment in primary human epidermal keratinocytes (skin cells) infected with A. baumannii.
The WHO has listed A. baumannii as one of the top priority pathogens due to its high levels of resistance to multiple antibiotics. A. baumannii is now a significant global health threat, known for causing severe infections, both in hospital settings and within the community.
Prevalent infections from A. baumannii include persistent wound infections, central line-associated bloodstream infections (BSIs), catheter-associated Urinary Tract Infections (UTIs), ventilator-associated pneumonia (VAP), and meningitis. Infections caused by MDR A. baumannii can lead to prolonged hospital stays, increased healthcare costs, and high mortality rates, with some studies reporting mortality rates as high as 50% in critically ill patients.
July 12, 2024
